Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Neurodegenerative Diseases

• Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
• Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
• A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
• A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
• A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
• A Trial of Lu AF82422 in Participants With Multiple System Atrophy (MSA)
• A Phase 3 Study of NTLA-2001 in ATTRv-PN
• Clinical Study of HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
• Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS
• A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
• Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects
• A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
• Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
• An Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
• A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01
• Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
• Probiotics in Mild Alzheimer's Disease
• MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease
• AMX0035 and Progressive Supranuclear Palsy
• Continuation Study for Latozinemab
• A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
• [18F]MC225-PET in Neurodegenerative Disease
• A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
• Role of Saffron and Chamomile in the Management of Parkinson's Disease
• Statins in Reducing Events in the Elderly Mind (STAREE-Mind) Imaging Substudy
• AMDX-2011P Retinal Tracer in Subjects With Neurodegenerative Diseases Associated With Amyloidogenic Proteinopathy
• A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
• An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
• Immunohistochemical Study of Neurodegenerative Diseases
• A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
• Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients
• Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
• Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
• Study to Assess the Efficacy of XPro™ in Patients With Mild Alzheimer's Disease With Biomarkers of Inflammation
• A FIH Study to Assess the Safety and Tolerability of NS Intravenous NS101 Infusion
• Dopaminergic Therapy for Frontotemporal Dementia Patients
• Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders
• Role and Mechanism of Probiotics in Improving Motor Symptoms in Mild to Moderate Parkinson's Disease
• Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
• A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders
• A First in Human Study to Assess the Safety,Tolerability and Pharmacokinetics of ONO-2808 in Healthy Participants
• Exploratory Evaluation of [11C]MPC6827
• Tocotrienols in Parkinson's Disease (PD)
• Multidisciplinary Study of Novel NMDA Modulation for Neurodegenerative Disorder
• Clinical Curative Effect Evaluation Study of Treatment of Oral Deferiprone Tablets in Aceruloplasminaemia Patients
• Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
• Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety
• Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies
• Citicoline Concentration in Human Vitreous
• PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand
• Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease. Extension to HP-CD-CL-2002 Clinical Study
• Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
• A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
• A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831
• To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.
• Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease
• PET Tau - Neurodegenerative Disease Imaging
• AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
• Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
• [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
• Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS
• Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
• Reproducibility of the 11C-PBR28 PET Signal
• Effect of Nicotinamide in Friedreich's Ataxia
• Evaluation of Web-based Training to Educate Physicians in the Methods of Interpreting Florbetapir-PET Scans
• Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
• Prediction of Cognitive Properties of New Drug Candidates for Neurodegenerative Diseases in Early Clinical Development
• DaTSCAN Imaging in Aging and Neurodegenerative Disease
• Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
• Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
• Dyskinesia in Parkinson's Disease (Study P04501)
• Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects
• Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System